

We claim:

1. A receptor for human parvovirus B19, consisting essentially of a protein having the amino acid sequence shown in SEQ ID NO:1 in SEQUENCE LISTING, or a protein having the same amino acid sequence as shown in SEQ ID NO:1 except that a small number of amino acid residues are substituted or deleted, or a small number of amino acid residues are inserted or added, which protein binds to human parvovirus B19.  
5
2. The receptor for human parvovirus B19 according to claim 1, consisting essentially of a protein having the amino acid sequence shown in SEQ ID NO:1 in SEQUENCE LISTING, or a protein having the same amino acid sequence as shown in SEQ ID NO:1 except that one to several amino acid residues are substituted or deleted, or one to several amino acid residues are inserted or added, which protein binds to human parvovirus B19.  
10
3. The receptor for human parvovirus B19 according to claim 1, consisting essentially of a protein having the amino acid sequence having a homology of not less than 90% with the amino acid sequence shown in SEQ ID NO:1.  
15
4. The receptor for human parvovirus B19 according to claim 1, wherein said protein has the amino acid sequence shown in SEQ ID NO:1.
5. An agent for binding human parvovirus B19, consisting essentially of said receptor for human parvovirus B19 according to any one of claims 1 to 4, or a virus-binding fragment thereof.  
20
6. A reagent for measuring human parvovirus B19, comprising said agent for binding human parvovirus B19 according to claim 5.
7. An agent for adsorbing human parvovirus B19, comprising said agent for binding human parvovirus B19 according to claim 5.  
25
8. An agent for suppressing infection by human parvovirus B19, comprising said agent for binding human parvovirus B19 according to claim 5.

9. An agent for suppressing infection by human parvovirus B19, comprising as an effective ingredient a substance which inhibits binding between said receptor for human parvovirus B19 according to any one of claims 1 to 4 and human parvovirus B19.
- 5 10. The agent for suppressing infection according to claim 9, comprising as an effective ingredient an antibody which undergoes antigen-antibody reaction with said receptor for human parvovirus B19 according to any one of claims 1 to 4, or an antigen-binding fragment thereof.
- 10 11. A process for producing a cell which adsorbs human parvovirus B19 or which is sensitive to human parvovirus B19, comprising the step(s) of giving to a cell an ability to express said receptor for human parvovirus B19 according to any one of claims 1 to 4, and/or giving to a cell an ability to express P antigen.
- 15 12. A process for producing a cell which adsorbs human parvovirus B19 or which is sensitive to human parvovirus B19, comprising the steps of isolating a cell from a cell population, which expresses said receptor for human parvovirus B19 according to any one of claims 1 to 4, and isolating a cell from the cell population, that expresses P antigen.
- 20 13. A process for producing a cell which adsorbs human parvovirus B19 or which is sensitive to human parvovirus B19, comprising the step of isolating a cell from a cell population, which presents said receptor for human parvovirus B19 according to any one of claims 1 to 4.
14. The process according to claim 13, further comprising the step of isolating a cell from a cell population, which presents P antigen.